Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis
Huihui Dai, Chang Liu, Peijuan Li and 8 more
Translational Oncology · 2020
doi:10.1016/j.tranon.2020.100779 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
OBJECTIVE: This meta-analysis was performed to investigate hyperlipidemia in patients with carcinoma treated with vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors. METHODS: We searched for eligible phase II and III studies using PubMed and Embase databases. We then summarized reported occurrences of hyperlipidemia in patients with different cancers. Relative risk ratios (RRs) and 95% confidence intervals (CIs) were calculated by Revman 5 software in meta-analysis. RESULTS: Eleven trials (4760 subjects) were included in this meta-analysis. Overall, VEGF/VEGFR inhibitors had similar incidence of hypertriglyceridemia (RR = 0.56, 95% CI = 0.24%-1.32%, P =.19), hypercholesterolemia (RR = 1.15, 95% CI = 0.42%-3.16%, P =.78), and LDL elevation (RR = 4.58, 95% CI = 0.80%-26.25%, P =.09) than control drugs, under high heterogeneity. Moreover, subgroup analyses found VEGF/VEGFR inhibitors had higher incidence of hypertriglyceridemia (RR = 1.86, 95% CI = 1.37%-2.52%, P <.001) and hypercholesterolemia (RR = 2.95, 95% CI = 2.02%-4.30%, P =.006) than blank control or placebo control drugs (placebo-controlled-group), although with lower incidence of hypertriglyceridemia (RR = 0.29, 95% CI = 0.12%-0.69%, P <.001) and hypercholesterolemia (RR = 0.39, 95% CI = 0.28%-0.56%, P <.001) than positive control drugs (positive-controlled-groups). CONCLUSION: The use of VEGF/VEGFR inhibitors, especially the multitargeted VEGFR tyrosine kinase inhibitors (VEGFR-TKIs), was associated with higher risk of hyperlipidemia than the use of placebo, but this risk was less than that associated with mTOR or FGFR inhibitors. It indicated that clinicians need to pay close attention to the occurrence of hyperlipidemia in VEGFR-TKIs therapies.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.